Objectives Conventional radiologic response criteria inadequately address imaging features and delayed responses after radiation-based therapies, limiting clinical decisions. This study evaluated treatment response to radiation-based locoregional therapies using modified RECIST (mRECIST), LI-RADS treatment response algorithm (LR-TRA) v2017, and radiation LR-TRA v2024, assessed changes in response categories during follow-up, and evaluated their association with overall survival (OS). Materials and Methods This single-center retrospective study included consecutive patients with hepatocellular carcinoma treated with transarterial radioembolization or external beam radiation therapy between 2011 and 2023. Two abdominal radiologists independently assessed the first radiologic response 3 months post-treatment using the mRECIST, LR-TRA v2017, and radiation LR-TRA v2024. The changes in the mRECIST and LR-TR categories during follow-up were evaluated. The Cox proportional hazard model was used to assess the association between response categories and OS. Results A total of 115 patients were included (66.6 ± 12.9 years; 73.9% [85/115] men). Complete response (CR), partial response, stable disease, and progressive disease (PD) based on the mRECIST were 36.5% (44/115), 26.1% (30/115), 17.4% (20/115), and 20% (26/115), respectively. In LR-TRA v2017, the nonviable, equivocal, and viable rates were 48.7% (56/115), 13% (15/115), and 38.3% (44/115), respectively. In LR-TRA v2024, the nonviable, nonprogressing, and viable rates were 47% (54/115), 51.3% (59/115), and 1.7% (2/115), respectively. During follow-up, the proportion of LR-TR nonprogressing decreased, while that of LR-TR nonviable increased over time. Achieving nonviable disease during follow-up was strongly associated with improved OS (p < 0.001). Conclusion Radiation LR-TRA v2024 effectively reflected a typical delayed response pattern after radiation-based therapy. Key Points <Emphasis Type="BoldItalic">Question</Emphasis> Conventional radiologic response criteria do not fully address the imaging features and delayed response pattern after radiation-based therapies, limiting clinical decision making. <Emphasis Type="BoldItalic">Findings</Emphasis> The new LI-RADS radiation treatment response assessment v2024 (LR-TRA v2024) effectively reflects unique post-treatment imaging features and delayed response to radiation-based treatment, facilitating management and communication. <Emphasis Type="BoldItalic">Clinical relevance</Emphasis> The new radiation LR-TRA v2024 captured the evolving nature of post-radiation imaging features by incorporating the concept of temporal change and LR-TR nonprogressing disease to allow for a watch-and-wait protocol. Graphical Abstract

Evaluation of the LI-RADS radiation treatment response assessment v2024 in comparison with the modified RECIST

期刊论文
发表日期：

2025年6月5日

查看全文

Hokun Kim,
Bohyun Kim,
Seok Hyun Son,
Jeong Won Jang,
Pil Soo Sung,
Joon-Il Choi,
Suho Kim,
Jung Suk Oh,
Ho Jong Chun

摘要

Objectives

Conventional radiologic response criteria inadequately address imaging features and delayed responses after radiation-based therapies, limiting clinical decisions. This study evaluated treatment response to radiation-based locoregional therapies using modified RECIST (mRECIST), LI-RADS treatment response algorithm (LR-TRA) v2017, and radiation LR-TRA v2024, assessed changes in response categories during follow-up, and evaluated their association with overall survival (OS).

Materials and Methods

This single-center retrospective study included consecutive patients with hepatocellular carcinoma treated with transarterial radioembolization or external beam radiation therapy between 2011 and 2023. Two abdominal radiologists independently assessed the first radiologic response 3 months post-treatment using the mRECIST, LR-TRA v2017, and radiation LR-TRA v2024. The changes in the mRECIST and LR-TR categories during follow-up were evaluated. The Cox proportional hazard model was used to assess the association between response categories and OS.

Results

A total of 115 patients were included (66.6 ± 12.9 years; 73.9% [85/115] men). Complete response (CR), partial response, stable disease, and progressive disease (PD) based on the mRECIST were 36.5% (44/115), 26.1% (30/115), 17.4% (20/115), and 20% (26/115), respectively. In LR-TRA v2017, the nonviable, equivocal, and viable rates were 48.7% (56/115), 13% (15/115), and 38.3% (44/115), respectively. In LR-TRA v2024, the nonviable, nonprogressing, and viable rates were 47% (54/115), 51.3% (59/115), and 1.7% (2/115), respectively. During follow-up, the proportion of LR-TR nonprogressing decreased, while that of LR-TR nonviable increased over time. Achieving nonviable disease during follow-up was strongly associated with improved OS (p < 0.001).

Conclusion

Radiation LR-TRA v2024 effectively reflected a typical delayed response pattern after radiation-based therapy.

Key Points

Question Conventional radiologic response criteria do not fully address the imaging features and delayed response pattern after radiation-based therapies, limiting clinical decision making.

Findings The new LI-RADS radiation treatment response assessment v2024 (LR-TRA v2024) effectively reflects unique post-treatment imaging features and delayed response to radiation-based treatment, facilitating management and communication.

Clinical relevance The new radiation LR-TRA v2024 captured the evolving nature of post-radiation imaging features by incorporating the concept of temporal change and LR-TR nonprogressing disease to allow for a watch-and-wait protocol.

Graphical Abstract